SAN

82.2

+0.46%↑

MRK1

118.95

-0.17%↓

SHL.DE

44.72

+0.61%↑

ARGX

726.2

-2.47%↓

FRE

47.89

+0.38%↑

SAN

82.2

+0.46%↑

MRK1

118.95

-0.17%↓

SHL.DE

44.72

+0.61%↑

ARGX

726.2

-2.47%↓

FRE

47.89

+0.38%↑

SAN

82.2

+0.46%↑

MRK1

118.95

-0.17%↓

SHL.DE

44.72

+0.61%↑

ARGX

726.2

-2.47%↓

FRE

47.89

+0.38%↑

SAN

82.2

+0.46%↑

MRK1

118.95

-0.17%↓

SHL.DE

44.72

+0.61%↑

ARGX

726.2

-2.47%↓

FRE

47.89

+0.38%↑

SAN

82.2

+0.46%↑

MRK1

118.95

-0.17%↓

SHL.DE

44.72

+0.61%↑

ARGX

726.2

-2.47%↓

FRE

47.89

+0.38%↑

Home・Akcijų sąrašas・RHOEN-KLINIKUM AG

RHOEN-KLINIKUM AG

Uždarymo kaina

11.8 -6.35

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

11.8

Max

12.9

Pagrindiniai rodikliai
By Trading Economics
Pajamos	2.9M 9.9M
Pardavimai	9.8M 429M
P/E Sektoriaus vid.	22.456 76.798
Pelnas, tenkantis vienai akcijai	0.148
Dividendų pajamingumas	0.78
Pelno marža	2.317
Darbuotojai	19,041
EBITDA	1M 27M

Dividendai
By Dow Jones
Dividendų pajamingumas Sektoriaus vid.	0.78% 2.37%

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	54M 857M
Ankstesnė atidarymo kaina	18.15
Ankstesnė uždarymo kaina	11.8

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

N/A / 15.2 Palaikymas ir pasipriešinimas

RHOEN-KLINIKUM AG Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-18 23:54; UTC

Karštos akcijos

Stocks to Watch: Nike, Cassava Sciences, KB Home

2025-12-18 23:51; UTC

Uždarbis

Nike Sales Tick Up in 2Q; China Weakness Persists -- Update

2025-12-18 23:39; UTC

Pagrindinės rinkos jėgos

Cassava Sciences Shares Fall After FDA Places Hold on Epilepsy Drug Trial

2025-12-18 22:57; UTC

Įsigijimai, susijungimai, perėmimai

TikTok Signs Agreement for Sale of U.S. Unit, Axios Reports, Citing a Memo

2025-12-18 21:40; UTC

Uždarbis

Nike Sales Tick Up, But China Weakness Persists

2025-12-18 23:45; UTC

Rinkos pokalbiai

Gold Steady, Supported by Fed Rate-Cut Prospects -- Market Talk

2025-12-18 23:37; UTC

Rinkos pokalbiai

Uždarbis

Nike 2Q Results Fail to Convince Investors of Recovery -- Market Talk

2025-12-18 23:36; UTC

Rinkos pokalbiai

Nikkei May Rise, Tracking Wall Street's Rally -- Market Talk

2025-12-18 23:03; UTC

Įsigijimai, susijungimai, perėmimai

Mitsubishi Materials: Impact on Consolidated Results for FY Ending March 2026 Likely to be Immaterial

2025-12-18 23:02; UTC

Įsigijimai, susijungimai, perėmimai

Mitsubishi Materials: To Acquire 4,448 Common Shares, 13,771 Preferred Shares of Co.

2025-12-18 23:00; UTC

Įsigijimai, susijungimai, perėmimai

Mitsubishi Materials: Investment to Strengthen Recovery Network in U.S.

2025-12-18 22:59; UTC

Įsigijimai, susijungimai, perėmimai

Mitsubishi Materials: Investment to Contribute to Expanding Collection Volume of Secondary Raw Material

2025-12-18 22:58; UTC

Įsigijimai, susijungimai, perėmimai

SpaceX Could Go Public by Merging With EchoStar. It Isn't a Crazy Idea. -- Barrons.com

2025-12-18 22:57; UTC

Įsigijimai, susijungimai, perėmimai

Mitsubishi Materials: Elemental USA E-Waste Operates E-Waste Recycling Business in U.S.

2025-12-18 22:56; UTC

Įsigijimai, susijungimai, perėmimai

Mitsubishi Materials: To Acquire Portion of Shares of Elemental USA E-Waste & ITAD

2025-12-18 22:55; UTC

Uždarbis

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

2025-12-18 21:59; UTC

Uždarbis

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

2025-12-18 21:50; UTC

Rinkos pokalbiai

Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2025-12-18 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-12-18 21:35; UTC

Uždarbis

FedEx's Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

2025-12-18 21:31; UTC

Uždarbis

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

2025-12-18 21:15; UTC

Uždarbis

Nike 2Q Europe, Middle East & Africa Rev $3.39B >NKE

2025-12-18 21:15; UTC

Uždarbis

Nike 2Q Greater China Rev Down 17% >NKE

2025-12-18 21:15; UTC

Uždarbis

Nike 2Q EPS 53c >NKE

2025-12-18 21:15; UTC

Uždarbis

Nike 2Q Apparel Rev $3.91B >NKE

2025-12-18 21:15; UTC

Uždarbis

Nike 2Q Equipment Rev $550M >NKE

2025-12-18 21:15; UTC

Uždarbis

Nike 2Q N Amer Rev $5.63B >NKE

2025-12-18 21:15; UTC

Uždarbis

Nike 2Q Footwear Rev $7.66B >NKE

2025-12-18 21:15; UTC

Uždarbis

Nike 2Q Asia Pacific & Latin America Rev Down 4% >NKE

2025-12-18 21:15; UTC

Uždarbis

Nike 2Q Greater China Rev $1.42B >NKE

Akcijų palyginimas

Kainos pokytis

RHOEN-KLINIKUM AG Prognozė

Bendras įvertinimas

By TipRanks

0 ratings

Pirkti

Laikyti

Parduoti

Remiantis 0 analitikų, pateikusių RHOEN-KLINIKUM AG akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

N/A / 15.2Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę RHOEN-KLINIKUM AG

RHÖN-KLINIKUM Aktiengesellschaft, together with its subsidiaries, offers in-patient, semi-patient, and outpatient healthcare services in Germany. It also operates acute hospitals, medical care centers, and rehabilitation hospitals. The company was founded in 1973 and is based in Bad Neustadt an der Saale, Germany.